Pioneering Botanical Therapies for Inflammatory and Neurological Diseases
Investor Summary | 2025
Transforming the $1.6 Trillion Pharma Industry with Polyphenol-Based Drug Innovation
Canurta Therapeutics is pioneering a new era in botanical medicine. We develop novel drugs from rare polyphenols—such as Cannflavin A & B—to address inflammatory and neurological conditions, beginning with ALS.
Led by a seasoned team with deep expertise in botanical drug development science and clinical development, our pipeline includes trial-ready and preclinical assets backed by global IP, regulatory momentum, and a transformative approach to drug discovery.
Why Invest
Innovative Pipeline
CNR-401 leads a growing pipeline targeting ALS, Alzheimer’s, and inflammation—built on multi-pathway compounds and validated preclinical data.
Breakthrough Compounds
Cannflavins A & B—30x stronger than aspirin—are exclusive to Canurta.
Regulatory & Market Traction
Orphan Drug paths in the U.S. and EU, with global entry points in Australia, Canada, Brazil and Germany.
AI-Driven Drug Development
PolyKye™ accelerates adaptive, multi-target drug development and enables precision across a scalable pipeline.
Proven Leadership
Veterans from GW Pharma—recognized for securing FDA approval of a plant-derived therapeutic and advancing botanical drug development.
Early Revenue
ALS programs launch in 2025 with multi-year agreements totaling up to $67M across Brazil and Germany.
Pioneers in Botanical Therapeutics
Founded in 2021, Canurta develops polyphenol-based drugs for neurological and inflammatory conditions. Our lead candidate, CNR-401, enters ALS trials in 2025 with early commercial programs in Brazil and Germany. Backed by over $13M in capital and $3.22M in non-dilutive funding, global IP, and GMP infrastructure, we are bridging nature with next-generation medicine.
The Problem and Our Solution
The Problem
Chronic inflammation and neurodegeneration underpin many of the world’s most devastating conditions. Current treatments are slow to develop, limited in efficacy, and often mono-targeted.
The Solution
Canurta’s therapies use rare polyphenols to target multiple pathways simultaneously. With a strong safety profile, our standardized, clinically-guided formulations offer a novel alternative to traditional single-target approaches.
CNR-401: A Botanical Breakthrough for ALS
CNR-401 is a proprietary liquid botanical drug composed of 10 active compounds, including cannflavin A, designed to relieve symptoms and slow disease progression in ALS and other neurodegenerative diseases. First-in-human trials will begin in 2025.
CBD
Other Minor Constituents
Terpenoids
CFA
Preclinical Highlights
-
Restored 85% motor function in zebrafish ALS model
-
Broader gene modulation than Edaravone, including NOS2 and DOCK2
-
Reduced anxiety-like behavior by 80%, with effects comparable to CBD
-
Confirmed non-toxicity at therapeutic doses
Mechanism of Action (MoA)
CNR-401 targets multiple systems impacted by ALS:
-
Neuron Survival – Anti-inflammatory, reduces glutamate toxicity
-
Motor Function – Enhances spasticity, coordination, and strength
-
Respiratory Health – Improves lung function and secretion clearance
-
Cognitive & Emotional – Reduces anxiety and supports mood
-
Cellular Defense – Boosts mitochondrial and antioxidant function
CNR-401 vs. Standard ALS Therapies
Feature | CNR-401 | Edaravone | Riluzole |
|---|---|---|---|
Annual Cost | ~30K CAD (NA) | ~$185K | ~$5.4K |
IP & Exclusivity | Global patents + 7-10 yrs exclusivity | Expired | Expired |
Regulatory Path | Botanical + Orphan | Small molecule | Small molecule |
Mechanism | Multi-target | Single Target: Free radical scavenger | Single Target: Glutamate inhibition |
Symptom Relief | Broad | None | Limited |
Disease Modification | Strong Potential | Modest | Modest |
Safety Profile | Oral, favorable | IV, known side effects | Requires live monitoring |
The Backbone: Cannflavins
Cannflavins A & B are rare polyphenols with 30x the anti-inflammatory potency of aspirin. They inhibit key enzymes like mPGES-1 and 5-LO, showing efficacy comparable to Zileuton, with broader therapeutic potential across neuroprotection and pulmonary health. Canurta holds exclusive global IP across extraction, formulation, and therapeutic use.
The Engine: Polykye™
PolyKye™ is Canurta’s proprietary AI platform that transforms rare plant compounds into next-gen therapies. It predicts compound behavior, adapts based on lab and clinical data, and enables ongoing optimization—cutting R&D timelines and powering a continuously evolving pipeline. Blockchain tracking across development stages ensures data integrity and transparent decision-making.
Business Model
Canurta is built for scalable growth through a diversified approach:
Botanical Rx:
Global drug development for ALS, neurological and inflammatory diseases
Licensing &
Co-Development:
IP and formulation partnerships with pharma
Vertical Integration:
Canurta Naturals, our parallel nutraceutical line
Go-to-Market Strategy
Early access programs in Brazil and Germany generate early revenue and real-world evidence (RWE) to fuel global expansion.
Brazil
ANVISA-approved Compassionate Use entry, distributor secured
Germany
Early ALS access under existing medical frameworks for plant-based therapeutics; partner discussions in progress.
RWE
Informs trial design and supports regulatory acceleration
Market Opportunity
$60B+ neurodegenerative disease market
$969M ALS market by 2028
Only two FDA-approved botanical drugs exist today—an untapped category
CNR-401 serves as a pipeline-in-a-product for ALS, Alzheimer’s, and beyond
7–10 years market exclusivity via Orphan Drug protections
Projected Neurodegenerative Disease Market
Our Traction
Over $13M total funding to date ($3.22M non-dilutive)
$11M Sales Contract & Carmen's Medicinals (Brazil), backed by Export Development Canada
23 patents filed across 7 major markets (US, CA, EU, MX, IN, CN, BR)
GMP manufacturing in U.S. with global reach
HALOS first-in-human trial launches in Australia (IND exempt) in Q3 2025
Commercial pilots launch Q4 2025 (Brazil + Germany)
AI platform PolyKye™ in early MVP stage
Strategic partnerships with top clinical and academic groups
Team
Therapeutic Pipeline
Canurta leverages patented technology to unlock the blockbuster potential of rare polyphenols, creating multi-target, disease-specific formulations for inflammatory and neurological diseases. Its lead molecules, cannflavins A and B, serve as the foundation for breakthrough therapies.
Investment Opportunity
$15M CAD Convertible Note
Cap: TBD | Close: Q4 2025
Liquidity Events
Liquidity Event Target: Before End of Q2 2026
Alternative Exits: Licensing / Acquisition (e.g., GW Pharma $7.2B)
ROI Potential: Up to 102.8x
What's Next
ALS pilots launch in Brazil & Germany (early access + RWE) (Q3 2025)
U.S. IND, confirmatory trials, public listing prep (2026)
FDA pre-IND and Orphan Drug Designation (Q1 2025)
HALOS first-in-human trial (Australia) (Q3/Q4 2025)
